Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2017 1
2018 1
2020 2
2021 2
2022 3
2023 2
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD; endTB Clinical Trial Team. Guglielmetti L, et al. Among authors: lachenal n. N Engl J Med. 2025 Jan 30;392(5):468-482. doi: 10.1056/NEJMoa2400327. N Engl J Med. 2025. PMID: 39879593 Free PMC article. Clinical Trial.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang'wa B-T, Fielding KL, Berry C. Motta I, et al. Among authors: lachenal n. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0053624. doi: 10.1128/aac.00536-24. Epub 2024 Jun 6. Antimicrob Agents Chemother. 2024. PMID: 38842323 Free PMC article. Clinical Trial.
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis.
Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR; endTB Study Group; Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Velásquez GE, Williams B, Yim JJ, Savic R, Hesseling A. Garcia-Prats AJ, et al. Among authors: lachenal n. Lancet Child Adolesc Health. 2025 Feb;9(2):100-111. doi: 10.1016/S2352-4642(24)00330-4. Lancet Child Adolesc Health. 2025. PMID: 39855750
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Among authors: lachenal n. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, Tigay Z, Liverko I, Usmanova R, Butabekov I, Moodliar R, Mbenga M, Rasool M, Nyang'wa BT, Berry C. Crocker-Buque T, et al. Among authors: lachenal n. Clin Infect Dis. 2024 Aug 16;79(2):569-570. doi: 10.1093/cid/ciad767. Clin Infect Dis. 2024. PMID: 38419566 Free PMC article. No abstract available.
The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort.
Khan U, Rich M, Franke MF, Lachenal N, Ahmed S, Bekele A, Isani AK, Hewison C, Sari CYI, Tan CL, Varaine F, Flores EH, Putri FA, Faqirzai J, Beauchamp J, Vo LNQ, Siddiqui MR, Seung K, Bastard M, Nkunkanyirazo P, Kiria N, Khan M, Algozhin Y, Melikyan N, Saki NA, Vilbrun SC, Fatima R, Naing YY, Islam S, Mamsa S, Mitnick CD, Huerga H, Khan PY. Khan U, et al. Among authors: lachenal n. Clin Infect Dis. 2025 Aug 1;81(1):153-158. doi: 10.1093/cid/ciae601. Clin Infect Dis. 2025. PMID: 39658125 Free PMC article.
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.
Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, Yatskevich N, Solodovnikova V, Viatushka D, Parpieva N, Safaev K, Liverko I, Tigay Z, Moe S, Khristusev A, Allamuratova S, Mirzabaev S, Achilov M, Samieva N, Lachenal N, Merle CS, Sall FB, Restrepo CG, Tan C, Sitali N, Saunders MJ. Sinha A, et al. Among authors: lachenal n. Clin Infect Dis. 2025 Nov 6;81(4):838-845. doi: 10.1093/cid/ciaf035. Clin Infect Dis. 2025. PMID: 39964841 Free PMC article.
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Hewison C, Khan U, Bastard M, Lachenal N, Coutisson S, Osso E, Ahmed S, Khan P, Franke MF, Rich ML, Varaine F, Melikyan N, Seung KJ, Adenov M, Adnan S, Danielyan N, Islam S, Janmohamed A, Karakozian H, Kamene Kimenye M, Kirakosyan O, Kholikulov B, Krisnanda A, Kumsa A, Leblanc G, Lecca L, Nkuebe M, Mamsa S, Padayachee S, Thit P, Mitnick CD, Huerga H. Hewison C, et al. Among authors: lachenal n. Clin Infect Dis. 2022 Sep 29;75(6):1006-1013. doi: 10.1093/cid/ciac019. Clin Infect Dis. 2022. PMID: 35028659 Free PMC article.
20 results